71 active not recruiting, 34 completed, 23 recruiting, 10 terminated. 84 Phase 2, 65 Phase 1, 9 Not applicable, 3 Phase 3, 2 Phase 4.
Follow Advanced Malignant Solid Neoplasm: new trials by email Literature Review of Advanced Malignant Solid Neoplasm trials Research Report on Advanced Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adoption of Audio Recording in the Outpatient Supportive Care Center Communication Intervention, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2026-12-30 | 2026-07-16 | |
| Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor Trastuzumab Rezetecan - Solid Tumors, Neoplasms (Cancer / Tumors) | Phase 2 | Not yet recruiting | Haihua Yuan | 15 | 2026-06-15 | 2026-06-08 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person Supportive Care, Telephone-Based Intervention, Survey Administration - Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm | Not applicable | Recruiting | Fred Hutchinson Cancer Center | 80 | 2026-04-08 | 2026-08-25 |
| TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma TR-002 - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | University of California, Davis | 52 | 2025-11-07 | 2026-07-16 |
| Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors Advance Care Planning, Educational Intervention, Electronic Health Record Review - Advanced Malignant Solid Neoplasm, Malignant Brain Neoplasm | Not applicable | Recruiting | Mayo Clinic | 50 | 2025-09-02 | 2026-07-08 |
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| Studying TAK-243 in Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 95 | 2025-03-24 | 2026-10-13 |
| Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 500 | 2025-03-18 | 2026-10-20 |
| Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients Best Practice, Electronic Health Record Review, Interview - Advanced Malignant Solid Neoplasm, Delirium | Phase 4 | Withdrawn | Mayo Clinic | 2025-02-26 | 2025-05-01 | |
| Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial Biospecimen Collection, Dietary Intervention, Educational Intervention - Advanced Malignant Solid Neoplasm | Not applicable | Terminated | Mayo Clinic | 2 | 2024-11-11 | 2026-08-31 |
| Group Meaning-Centered Psychotherapy for the Improvement of Wellbeing in Caregivers of Patients With Serious Illness Behavioral Counseling, Discussion, Health Promotion and Education - Advanced Malignant Solid Neoplasm | Not applicable | Enrolling by invitation | Mayo Clinic | 80 | 2024-09-12 | 2026-08-07 |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 105 | 2024-08-01 | 2026-10-22 |
| Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Withdrawn | Mayo Clinic | 2024-07-30 | 2025-01-07 | |
| Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer Olanzapine, Placebo Administration, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 66 | 2024-07-17 | 2026-07-16 |
| Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy - Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Recruiting | Yuanquan Yang | 40 | 2024-07-09 | 2026-09-28 |
| Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 35 | 2024-06-12 | 2026-10-15 |
| Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 66 | 2024-06-07 | 2026-08-24 |
| Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors Axatilimab, Biopsy, Biospecimen Collection - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 38 | 2024-05-21 | 2026-07-08 |
| Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 42 | 2023-09-28 | 2026-07-31 |
Showing 20 of 152. Sign in to see all of them.
Neoplasm Metastasis (56) · Lymphoma (39) · Multiple Myeloma (36) · Hematologic Neoplasms (26) · Ovarian Neoplasms (14) · Pancreatic Neoplasms (14) · Glioma (12) · Lung Neoplasms (12) · Lymphoma, Non-Hodgkin (11) · Neuroblastoma (11) · Ependymoma (10) · Hepatoblastoma (10) · Histiocytosis, Langerhans-Cell (10) · Melanoma (10) · Neuroectodermal Tumors, Primitive, Peripheral (10)
Neoplasms (132) · Neoplasms by Site (85) · Neoplasms by Histologic Type (78) · Pathological Conditions, Signs and Symptoms (60) · Pathologic Processes (57) · Hemic and Lymphatic Diseases (56) · Neoplastic Processes (56) · Immune System Diseases (54) · Immunoproliferative Disorders (51) · Lymphoproliferative Disorders (51) · Lymphatic Diseases (50) · Hematologic Diseases (42) · Cardiovascular Diseases (37) · Vascular Diseases (37) · Blood Protein Disorders (36)
Specimen Handling (47) · Biopsy (42) · Magnetic Resonance Spectroscopy (38) · X-Rays (13) · Nivolumab (11) · Nuclear Medicine Department, Hospital (9) · Paclitaxel (9) · Taxes (9) · olaparib (9) · palbociclib (8) · trametinib (8) · Phantoms, Imaging (7) · CTLA-4 Antigen (6) · Crizotinib (6) · Disulfides (6)
National Cancer Institute (NCI) (84) · M.D. Anderson Cancer Center (32) · Mayo Clinic (9) · OHSU Knight Cancer Institute (5) · Roswell Park Cancer Institute (3) · University of California, Davis (3) · University of Southern California (2) · Alliance for Clinical Trials in Oncology (1) · Fred Hutchinson Cancer Center (1) · Haihua Yuan (1) · Jonsson Comprehensive Cancer Center (1) · Northwestern University (1) · RasCal Therapeutics, Inc. (1) · Ronald Levy (1) · SWOG Cancer Research Network (1)
United States (146) · Puerto Rico (14) · Canada (6) · Australia (3) · Guam (1)
Timothy A Yap (7) · David S Hong (4) · Filip Janku (4) · Patricia M LoRusso (4) · Siqing Fu (4) · Sriram Yennu (4) · Aung Naing (3) · Aung Naing, MD (2) · Funda Meric-Bernstam (2) · James M Cleary (2) · Jason J Luke (2) · John L Hays (2) · Kevin M Kalinsky (2) · Nilofer S Azad (2) · Sarina A Piha-Paul (2)
PMID 31401903, PMID 32463741, PMID 36351402, PMID 26586415, PMID 26602013, PMID 28265009, PMID 28428884, PMID 31533818, PMID 31765263, PMID 32188704, PMID 32303619, PMID 32534809, PMID 33048619, PMID 33115815, PMID 33415580, PMID 33427689, PMID 33491277, PMID 33591402, PMID 33677480, PMID 33706770, PMID 33770291, PMID 33909232, PMID 34241781, PMID 34331589, PMID 34486544, PMID 34562230, PMID 34725215, PMID 34965890, PMID 35130943, PMID 35133871, PMID 35135810, PMID 35138919, PMID 35353553, PMID 35363510, PMID 35396812, PMID 35618285, PMID 35999229, PMID 36052732, PMID 36469840, PMID 36658425, PMID 36765881, PMID 37036756, PMID 37053535, PMID 37129197, PMID 37314501, PMID 37322121, PMID 37568622, PMID 37823909, PMID 37934000, PMID 37962072
U10CA180820 (38), U24CA196172 (21), U10CA180886 (11), UM1CA186688 (10), UM1CA186689 (8), P30CA016672 (7), UM1CA186709 (6), P30CA093373 (4), U01CA062490 (3), UM1CA186716 (3), UM1CA186717 (3), ZIABC011078 (3), P30CA014089 (2), P30CA072720 (2), U01CA062487 (2)